Glaukos Corporation $GKOS Shares Newly Acquired by New York Life Investment Management LLC

New York Life Investment Management LLC purchased a new stake in Glaukos Corporation (NYSE:GKOS – Free Report) in the third quarter, HoldingsChannel.com reports. The firm purchased 8,801 shares of the medical instruments supplier’s stock, valued at approximately $1,445,000.

Other institutional investors have also added to or reduced their stakes in the company. Parallel Advisors LLC grew its stake in shares of Glaukos by 14.4% during the third quarter. Parallel Advisors LLC now owns 438 shares of the medical instruments supplier’s stock worth $72,000 after acquiring an additional 55 shares during the last quarter. State of Wyoming increased its holdings in shares of Glaukos by 6.8% during the third quarter. State of Wyoming now owns 1,030 shares of the medical instruments supplier’s stock valued at $169,000 after acquiring an additional 66 shares in the last quarter. Fulcrum Asset Management LLP increased its holdings in shares of Glaukos by 91.7% during the third quarter. Fulcrum Asset Management LLP now owns 184 shares of the medical instruments supplier’s stock valued at $29,000 after acquiring an additional 88 shares in the last quarter. Wealth Alliance LLC increased its holdings in shares of Glaukos by 4.5% during the first quarter. Wealth Alliance LLC now owns 2,297 shares of the medical instruments supplier’s stock valued at $247,000 after acquiring an additional 98 shares in the last quarter. Finally, Abel Hall LLC raised its position in shares of Glaukos by 3.5% in the 3rd quarter. Abel Hall LLC now owns 3,236 shares of the medical instruments supplier’s stock valued at $531,000 after purchasing an additional 108 shares during the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Insider Activity

In related news, Director Gilbert Kliman sold 2,500 shares of Glaukos stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $253.00, for a total transaction of $632,500.00. Following the completion of the sale, the director owned 37,406 shares of the company’s stock, valued at $9,463,718. The trade was a 6.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 5.90% of the stock is currently owned by insiders.

Glaukos Stock Performance

Shares of GKOS opened at $245.60 on Monday. The stock has a 50-day moving average of $184.61 and a two-hundred day moving average of $147.10. Glaukos Corporation has a one year low of $87.32 and a one year high of $255.18. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.09 and a current ratio of 4.57. The stock has a market cap of $14.54 billion, a P/E ratio of -83.54 and a beta of 0.68.

Glaukos (NYSE:GKOS – Get Free Report) last posted its quarterly earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.57. The business had revenue of $211.03 million for the quarter, compared to the consensus estimate of $168.04 million. Glaukos had a negative return on equity of 0.97% and a negative net margin of 24.60%. The company’s quarterly revenue was up 58.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.16) EPS. As a group, research analysts predict that Glaukos Corporation will post 0.50 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently commented on the stock. JPMorgan Chase & Co. lifted their target price on shares of Glaukos from $200.00 to $240.00 and gave the stock an “overweight” rating in a research note on Thursday, October 29th. Stifel Nicolaus boosted their target price on shares of Glaukos from $190.00 to $225.00 and gave the stock a “buy” rating in a research report on Thursday, October 29th. Needham & Company LLC upped their price target on shares of Glaukos from $201.00 to $251.00 and gave the company a “buy” rating in a research note on Thursday, October 29th. Piper Sandler restated an “overweight” rating and set a $240.00 price target (up from $195.00) on shares of Glaukos in a research note on Thursday, October 29th. Finally, Zacks Research raised shares of Glaukos from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 28th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $216.71.

Read Our Latest Report on Glaukos

Glaukos Profile

(Free Report)

Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes treatments for glaucoma and other eye disorders. Its portfolio includes minimally invasive glaucoma surgery (MIGS) devices, such as the iStent family, and iDose TR, an implant designed to deliver glaucoma medication inside the eye over an extended period. The company also offers products for corneal disorders, including technology used in corneal cross-linking procedures to treat keratoconus and other conditions that weaken the cornea.

Further Reading

Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS – Free Report).

Institutional Ownership by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.